Gunnar Henrik Heine/X
Jun 23, 2025, 13:27
Gunnar Henrik Heine: Apixaban Substantially Safer than Rivaroxan for Initial Treatment of VTE
Gunnar Henrik Heine, Professor of Internal Medicine at Saarland University, Editor of Nephrology Dialysis Transplantation (NDT), shared a post on X:
“RivaGate in DC at ISTH 2025. In COPRRA, apixaban was substantially safer than rivaroxan for initial (3 mo) treatment of VTE.
Lana Castellucci for this arguably most important DOAC study ever.”
More posts from ISTH 2025 on Hemostasis Today.
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications
-
Jan 6, 2026, 09:52Antoine Francis: Plasma is Not Just Another Component of Healthcare…
-
Jan 6, 2026, 09:45Hurry to Join EHC Youth Leadership Workshop 2026
-
Jan 6, 2026, 09:41Andrew Petrosoniak Makes It to N1 on EMCases Best of 2025!
-
Jan 6, 2026, 09:35Sara Ng: Moving Beyond Management to Stewardship – “Advancing Anticoagulation Stewardship” Released by NQF
-
Jan 6, 2026, 09:30Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B
-
Jan 6, 2026, 09:09Abdulrahman Nasiri: A New Perspective on Avatrombopag in Aplastic Anemia